
    
      This is an open-label, randomized, active-controlled pilot study to evaluate the efficacy and
      safety profile of topical MW-III versus an active control (SilvadeneÂ® Cream 1% [Silver
      Sulfadiazine]) in the treatment of second-degree thermal burns in adults. Approximately 30
      subjects per treatment group will be enrolled and 60 subjects in total.
    
  